Altogether, in this study of temporal evolution in an unbiased multi-omics approach, with further validation studies in mouse nervous tissues and human blood sera, SERPINB1 was identified as the most promising novel candidate, which should be evaluated for its utility as progression biomarker for SCA2. Here, SERPINB1 is linked to spinocerebellar ataxia type 2.